Is REmogliflozin an effective Drug in MANaging Type-2 diabetes mellitus: A comparative study – (REDMAN)

Abstract

Background and Aims: Remogliflozin is a new addition to class of Sodium Glucose Cotransporter-2 (SGLT-2) inhibitors available in India. The drug is introduced and marketed at a lower price range as compared to other gliflozins. Remogliflozin is expected to gain preference over other gliflozins as it is cheaper. However, the pragmatic value of remogliflozin in establishing and maintaining blood glucose control is yet to be established. This objective of this study was to establish the efficacy of remogliflozin in maintaining glycemic control in patients of T2DM when switching from other gliflozins.Methods: The study was conducted for a duration of four months in 159 diabetic patients, previously on combination of one gliflozin and other anti-hyperglycaemic agents. Patients were prescribed remogliflozin with instructions to not modify their dietary practices. Pre- and post-remogliflozin switch levels of conjugated haemoglobin were used to ascertain the effect of the drug on patients.Results: The mean pre- and post-remogliflozin switch HbA1c levels were found to be significantly different (p<0.000). HbA1c levels increased marginally but significantly in the patients after switching to remogliflozin. There were significant differences in the mean HbA1c levels and the mean difference in HbA1c levels among the patients switching from empagliflozin, canagliflozin or dapagliflozin.Conclusion: Although, remogliflozin is comparatively cheap and is a potential drug of choice for patients of T2DM to reduce their out-of-pocket expenditure. Its potential to maintain optimum glycemic control in diabetic patients is limited and its use and prescription required vigilant monitoring.